Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stem cell-derived secretome + autologous plasma rich in growth factors
- Development stage
- Unknown
- Lead developer
- University of the Punjab
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraarticular
01
Overview
This investigational combination biologic therapy is being developed by the University of the Punjab for the treatment of knee osteoarthritis. It consists of a cell-free secretome derived from cultured mesenchymal stem cells (MSCs) combined with autologous plasma rich in growth factors (PRGF). The secretome contains a concentrated array of bioactive molecules, including cytokines and extracellular vesicles, while the PRGF provides a scaffold and additional growth factors to stimulate tissue regeneration. Administered via intra-articular injection under ultrasound guidance, the therapy aims to reduce inflammation, alleviate pain, and promote the repair of damaged articular cartilage in patients with mild to moderate knee osteoarthritis.
- Other names
- MSC-derived secretome + autologous PRGFMSC-derived secretome + PRGF
02
Targets
EGFR (Epidermal growth factor receptor)IGF-1R (Insulin-like growth factor 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)TGFBR (TGF-beta receptor)VEGFR (VEGFR family)
Beyond the preview
Go deeper on mesenchymal stem cell-derived secretome + autologous plasma rich in growth factors.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stem cell-derived secretome + autologous plasma rich in growth factors.